Author Title Type [ Year(Desc)]
Filters: Author is Niederwieser, Dietger  [Clear All Filters]
Shimoni, A., Labopin, M., Savani, B., Byrne, M., Volin, L., Finke, J., Niederwieser, D., Ehninger, G., Blaise, D., Beelen, D., et al. (2019). Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT.Biol Blood Marrow Transplant.
Ringdén, O., Boumendil, A., Labopin, M., Canaani, J., Beelen, D., Ehninger, G., Niederwieser, D., Finke, J., Stelljes, M., Gerbitz, A., et al. (2019). OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.
Beelen, D.Wilhelm, Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., Wagner-Drouet, E.-M., Hauptrock, B., Dreger, P., Luft, T., et al. (2019). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 .Lancet Haematol.
Pasquini, M.C., Srivastava, A., Ahmed, S.Osman, Aljurf, M., Atsuta, Y., Doleysh, C., Galeano, S., Gluckman, E., Greinix, H., Hale, G., et al. (2019). Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.Hematol Oncol Stem Cell Ther.